Download MendeleyDesign, Synthesis, and Characterization of GluN2A Negative Allosteric Modulators Suitable for In Vivo Exploration.
Bischoff, F.P., Van Brandt, S., Viellevoye, M., De Cleyn, M., Surkyn, M., Carbajo, R.J., Dominguez Blanco, M., Wroblowski, B., Karpowich, N.K., Steele, R.A., Schalk-Hihi, C., Miller, R., Duda, D., Shaffer, P., Ballentine, S., Simavorian, S., Lord, B., Neff, R.A., Bonaventure, P., Gijsen, H.J.M.(2025) J Med Chem 68: 4672-4693
- PubMed: 39960408
- DOI: https://doi.org/10.1021/acs.jmedchem.4c02751
- Primary Citation of Related Structures:
9MUL, 9MUM - PubMed Abstract:
N -Methyl-d-aspartate receptors are ionotropic glutamate receptors that mediate fast excitatory neurotransmission in the central nervous system. These receptors play essential roles in synaptic plasticity, learning, and memory and are implicated in various neuropathological and psychiatric disorders. Selective modulation of NMDAR subtypes, particularly GluN2A, has proven challenging. The TCN-201 derivatives MPX-004 and MPX-007 are potent and selective for GluN2A receptors, yet their physical properties limit their in vivo utility. In this study, we optimized the MPX-004 / MPX-007 scaffold by modifying the linker region between the distal halogenated aromatic ring and the central pyrazine nucleus, resulting in the identification of potent and selective compounds with improved drug-like properties. Notably, compound 1 was used to develop the first GluN2A NAM-based radioligand, and compound 11 showed improved pharmacokinetics and dose-dependent receptor occupancy in vivo. Thus, we provide an array of powerful new tools for the study of GluN2A receptors.
Organizational Affiliation:
Janssen Research & Development, Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse, Belgium.
